DPI：2023年现代化临床前和临床优化技术研究报告 （英文版）（44页）.pdf

1、Modern Technologiesfor Preclinical and ClinicalOptimisationwww.deep-pharma.techRelying on various research methods and analytics techniques,the analysis provides a comprehensive overview of the Preclinical and Clinical Trials Industry.This approach has certain limitations,especially when using publi

2、cly available data sources and conducting the secondary research.DPI is not responsible for the quality of the secondary data presented herein;however,we do our best to eliminate the said risks using different analytics techniques and cross-checking data.Please note that we did not deliberately excl

3、ude certain companies from our analysis.Nor was it due to the data-filtering method used or difficulties encountered.The main reason for their noninclusion was incomplete or missing information in the available sources.Report ApproachIndustry-Specialised Databases Data SourcesMedia Overview(Articles

4、 and Press Releases)Industry Reports and ReviewsPublicly Available Sources(Websites)DescriptiveAnalysisComparative AnalysisQualitative Data CollectionMixed Data ResearchData TriangulationData FilteringApplied Research and Analytics MethodsDatabase70Clinical Trials165Companies260InvestorsThe database

5、 was formed based on:the identification of companies that conduct or have conducted clinical or preclinical research of drugs the identification of companies that research or develops biomarkersDeep Pharma Intelligence2Market Size OverviewDeep Pharma Intelligence3Market Size GrowthCumulative Market

6、SizeMarket Size per YearMarket Size in$BYearTechnologies for preclinical and clinical optimization are becoming increasingly popular over the last few years.More and more companies specialising in the development of technologies for preclinical and clinical optimization are opening every year,and ev